Thermo Fisher Scientific Inc. $TMO Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 201.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,562 shares of the medical research company’s stock after acquiring an additional 33,146 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $28,997,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TMO. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. raised its holdings in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after acquiring an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $473.08 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market cap of $175.81 billion, a PE ratio of 26.01, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. The company’s 50 day simple moving average is $478.75 and its 200-day simple moving average is $526.39. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TMO shares. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a research note on Thursday. They issued a “neutral” rating and a $510.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $608.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.